182 related articles for article (PubMed ID: 38002095)
1. PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches.
Bui VN; Unterrainer LM; Brendel M; Kunte SC; Holzgreve A; Allmendinger F; Bartenstein P; Klauschen F; Unterrainer M; Staehler M; Ledderose S
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002095
[TBL] [Abstract][Full Text] [Related]
2. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
Baccala A; Sercia L; Li J; Heston W; Zhou M
Urology; 2007 Aug; 70(2):385-90. PubMed ID: 17826525
[TBL] [Abstract][Full Text] [Related]
3. Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.
Zschäbitz S; Erlmeier F; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Mondorf Y; Hartmann A; Ivanyi P; Steffens S
J Cancer; 2022; 13(6):1706-1712. PubMed ID: 35399715
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
5. High Prognostic Value of
Gasparro D; Scarlattei M; Silini EM; Migliari S; Baldari G; Cervati V; Graziani T; Campanini N; Maestroni U; Ruffini L
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835825
[TBL] [Abstract][Full Text] [Related]
6. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
7. Vascular Expression of Prostate-specific Membrane Antigen (PSMA) in MiTF Family Translocation Renal Cell Carcinoma and Related Neoplasms.
Baraban EG; Ged Y; Singla N; Allaf ME; Gorin MA; Markowski MC; Rowe SP; Argani P
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):544-549. PubMed ID: 37471632
[TBL] [Abstract][Full Text] [Related]
8. Expression of prostate-specific membrane antigen in renal cortical tumors.
Al-Ahmadie HA; Olgac S; Gregor PD; Tickoo SK; Fine SW; Kondagunta GV; Scher HI; Morris MJ; Russo P; Motzer RJ; Reuter VE
Mod Pathol; 2008 Jun; 21(6):727-32. PubMed ID: 18344976
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
10. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
[TBL] [Abstract][Full Text] [Related]
11. Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.
Sadaghiani MS; Baskaran S; Gorin MA; Rowe SP; Provost JC; Teslenko I; Bilyk R; An H; Sheikhbahaei S
J Nucl Med; 2024 May; ():. PubMed ID: 38782453
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cortico-medullary phase contrast-enhanced MDCT and T2-weighted MR imaging in the histological subtype differentiation of renal cell carcinoma: radiology-pathology correlation.
Halefoglu AM; Ozagari AA
Pol J Radiol; 2021; 86():e583-e593. PubMed ID: 34876939
[TBL] [Abstract][Full Text] [Related]
13. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere C; Bassanelli M; Ceribelli A; Rasul S; Li S; Prior JO; Cicone F
Curr Urol Rep; 2019 Oct; 20(11):68. PubMed ID: 31605269
[TBL] [Abstract][Full Text] [Related]
14. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
15. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
16. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
18. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
20. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Ahn T; Roberts MJ; Abduljabar A; Joshi A; Perera M; Rhee H; Wood S; Vela I
Mol Imaging Biol; 2019 Oct; 21(5):799-807. PubMed ID: 30617728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
